Phenagil Tablet
NDC Package 58552-337-01
Package Information
Phenagil (chlorpheniramine maleate, dextromethorphan hbr and phenylephrine hcl) tablets is • Adults and Children 12 years and over.: Take one tablet every 6-8 hours. This formulation utilizes a tablet delivery system. Marketed by Gil Pharmaceutical Corp., this product is identified by NDC 58552-337 and is authorized under FDA application M012.
Identification & Billing
- RxCUI: 2603661 - chlorpheniramine maleate 3.5 MG / dextromethorphan HBr 29 MG / phenylephrine HCl 10 MG Oral Tablet
- RxCUI: 2603661 - chlorpheniramine maleate 3.5 MG / dextromethorphan hydrobromide 29 MG / phenylephrine hydrochloride 10 MG Oral Tablet
Clinical Specifications
- Adrenergic alpha1-Agonists - [MoA] (Mechanism of Action)
- Histamine H1 Receptor Antagonists - [MoA] (Mechanism of Action)
- Histamine-1 Receptor Antagonist - [EPC] (Established Pharmacologic Class)
- Sigma-1 Agonist - [EPC] (Established Pharmacologic Class)
- Sigma-1 Receptor Agonists - [MoA] (Mechanism of Action)
- Uncompetitive N-methyl-D-aspartate Receptor Antagonist - [EPC] (Established Pharmacologic Class)
- Uncompetitive NMDA Receptor Antagonists - [MoA] (Mechanism of Action)
- alpha-1 Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 58552 - Gil Pharmaceutical Corp.
- 58552-337 - Phenagil
- 58552-337-01 - 100 TABLET in 1 BOTTLE
- 58552-337 - Phenagil
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (58552-337). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 58552-337-01 identifies a specific commercial package of 100 tablet in 1 bottle of Phenagil, a human over the counter drug labeled by Gil Pharmaceutical Corp.. This product is billed for "EA" each discreet unit and contains an estimated amount of 100 billable units per package. This tablet is formulated for oral use and contains chlorpheniramine maleate; dextromethorphan hydrobromide; phenylephrine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gil Pharmaceutical Corp. on May 26, 2022. The current certification is valid through December 31, 2026.
How is this Gil Pharmaceutical Corp. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 58552033701. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
